A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06988488 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Elranatamab
DRUG: Mezigdomide
DRUG: Dexamethasone

Sponsor

Celgene